Catalyst
Slingshot members are tracking this event:
Phase 3 IMpassion 130 data of AstraZeneca's (AZN) Tecentriq (atezolizumab) In breast cancer expected Q2 2018
- Source Link:
- https://clinicaltrials.gov/ct2/show/NCT02425891
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AZN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 02, 2018
Occurred Source:
https://www.roche.com/media/releases/med-cor-2018-07-02.htm
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Tecentriq, Atezolizumab, Breast Cancer
